Design and treatment
Tumors
ADVERSE EVENTS, TUMORS
Full details of the multicenter, open‐label, randomized, three‐arm, phase 3 CLEAR trial have been previously published (In this subset analysis of the CLEAR study, we investigated efficacy (PFS, OS, ORR, and DOR) and safety (any grade, grade ≥ 3, and serious treatment‐emergent adverse events [TEAEs]) in Japanese patients randomized to receive lenvatinib plus pembrolizumab or sunitinib treatment arms. Tumors were assessed by RECIST v1.1 per IIR.